RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Takeda - you want strong efficacy in ADHD, here it is. And CX-1739 or any of Cortex's other new low impacts will work even better than CX-717 did. Get your heads out of that bowl of chop suey and get on the phone to Cortex -->




Cortex - ADHD results - from the 10-K -



http://www.sec.gov/Archives/edgar/data/849636/000119312507054770/d10k.htm


>>> In early 2006, we reported that a three-week treatment with CX717 reduced symptoms of ADHD in adult patients. Forty-nine patients with ADHD completed the randomized, double-blind, placebo-controlled, two-way crossover design study. The primary outcome measure was the ADHD Rating Scale, which evaluates both the inattentiveness and hyperactivity symptoms. The overall ADHD Rating Scale score showed positive statistical changes in the ADHD Rating Scale scores (p<0.002) in the 800 mg twice daily dose group of 22 patients and also statistically significant effects on the hyperactivity subscale (p<0.01) and the inattentiveness subscale (p<0.03) compared to placebo. The 200 mg twice daily dose, tested in a group of 27 patients, did not show a significant effect. However, while the ADHD-RS values did not separate from the placebo values at the lower dose, they did show a trend for improvements in the ADHD-RS as dosing progressed from week 1 to week 3. CX717 was well tolerated, and there were no serious adverse events or other significant safety concerns with either dose. <<<